- Home
- JWEL vs MBRX Comparison
JWEL vs MBRX Comparison
Compare JWEL & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- MBRX
- Stock Information
- Founded
- JWEL 2012
- MBRX 2015
- Country
- JWEL China
- MBRX United States
- Employees
- JWEL N/A
- MBRX N/A
- Industry
- JWEL Other Consumer Services
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- MBRX Health Care
- Exchange
- JWEL Nasdaq
- MBRX Nasdaq
- Market Cap
- JWEL 6.0M
- MBRX 5.1M
- IPO Year
- JWEL 2021
- MBRX 2016
- Fundamental
- Price
- JWEL $2.91
- MBRX $1.15
- Analyst Decision
- JWEL
- MBRX Strong Buy
- Analyst Count
- JWEL 0
- MBRX 2
- Target Price
- JWEL N/A
- MBRX $24.00
- AVG Volume (30 Days)
- JWEL 17.0K
- MBRX 38.4K
- Earning Date
- JWEL 12-19-2024
- MBRX 03-21-2025
- Dividend Yield
- JWEL 7.34%
- MBRX N/A
- EPS Growth
- JWEL N/A
- MBRX N/A
- EPS
- JWEL N/A
- MBRX N/A
- Revenue
- JWEL $160,009,293.00
- MBRX N/A
- Revenue This Year
- JWEL N/A
- MBRX N/A
- Revenue Next Year
- JWEL N/A
- MBRX N/A
- P/E Ratio
- JWEL N/A
- MBRX N/A
- Revenue Growth
- JWEL N/A
- MBRX N/A
- 52 Week Low
- JWEL $1.00
- MBRX $0.40
- 52 Week High
- JWEL $3.71
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- JWEL 48.97
- MBRX 31.81
- Support Level
- JWEL $2.73
- MBRX $1.33
- Resistance Level
- JWEL $3.08
- MBRX $1.82
- Average True Range (ATR)
- JWEL 0.22
- MBRX 0.13
- MACD
- JWEL -0.03
- MBRX -0.02
- Stochastic Oscillator
- JWEL 41.38
- MBRX 13.17
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.